Efficacy and Safety of Perlane-L in the Correction of Midface Volume Deficit
Launched by MEDICIS GLOBAL SERVICE CORPORATION · Mar 27, 2012
Trial Information
Current as of May 21, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Loss of Fullness in Midface Area
- • Other items as identified in the protocol
- Exclusion Criteria:
- • History of allergy or hypersensitivity to injectable hyaluronic acid gel or lidocaine.
- • Other items as identified in the protocol
About Medicis Global Service Corporation
Medicis Global Service Corporation is a distinguished clinical trial sponsor dedicated to advancing healthcare through innovative research and development. With a strong commitment to improving patient outcomes, the organization specializes in conducting rigorous clinical trials across various therapeutic areas. Leveraging a team of experienced professionals and state-of-the-art methodologies, Medicis Global Service Corporation ensures the highest standards of safety, efficacy, and ethical practice in all its studies. By fostering collaboration with healthcare providers and regulatory bodies, the company aims to bring groundbreaking therapies to market, ultimately enhancing the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Francisco, California, United States
Chicago, Illinois, United States
Eugene, Oregon, United States
New York, New York, United States
Vista, California, United States
Beverly Hills, California, United States
Aventura, Florida, United States
Coral Gables, Florida, United States
Hunt Valley, Maryland, United States
Mount Kisco, New York, United States
Chestnut Hill, Massachusetts, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials